These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38727613)

  • 21. Miltefosine Induced Reduced Male Fertility Capacity after Treatment of Post Kala-azar Dermal Leishmaniasis, Bangladesh.
    Basher A; Rashid MM; Habibullah AM; Nath R; Akter D; Chowdhury IH; Azim A; Nath P; Faiz MA
    Mymensingh Med J; 2019 Apr; 28(2):328-332. PubMed ID: 31086147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis.
    Pijpers J; den Boer ML; Essink DR; Ritmeijer K
    PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007173. PubMed ID: 30742620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone.
    Mukhopadhyay D; Mukherjee S; Ghosh S; Roy S; Saha B; Das NK; Chatterjee M
    Int J Dermatol; 2016 May; 55(5):e250-5. PubMed ID: 26536363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A case report on para-kala-azar dermal leishmaniasis: an unresolved mystery.
    Hasan MM; Proma SB; Hossain MS; Arifuzzaman M; Islam N; Siddique MAB; Amiruzzaman
    BMC Infect Dis; 2023 Dec; 23(1):885. PubMed ID: 38110894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.
    Goyal V; Das VNR; Singh SN; Singh RS; Pandey K; Verma N; Hightower A; Rijal S; Das P; Alvar J; Bern C; Alves F
    PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008429. PubMed ID: 32687498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient.
    Abongomera C; Battaglioli T; Adera C; Ritmeijer K
    Int J Infect Dis; 2019 Apr; 81():221-224. PubMed ID: 30790722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis.
    Ramesh V; Katara GK; Verma S; Salotra P
    Br J Dermatol; 2011 Aug; 165(2):411-4. PubMed ID: 21561437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
    Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
    PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-kala-azar dermal leishmaniasis with mucosal involvement: an unusual case presentation including successful treatment with miltefosine.
    Salam MA; Siddiqui MA; Nabi SG; Bhaskar KR; Mondal D
    J Health Popul Nutr; 2013 Jun; 31(2):294-7. PubMed ID: 23930349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study.
    Younis BM; Mudawi Musa A; Monnerat S; Abdelrahim Saeed M; Awad Gasim Khalil E; Elbashir Ahmed A; Ahmed Ali M; Noureldin A; Muthoni Ouattara G; Nyakaya GM; Teshome S; Omollo T; Ochieng M; Egondi T; Mmbone M; Chu WY; Dorlo TPC; Zijlstra EE; Wasunna M; Alvar J; Alves F
    PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011780. PubMed ID: 37988402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of leishmaniasis with miltefosine: 2008 status.
    Berman JJ
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
    Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
    Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy.
    Belay AD; Asafa Y; Mesure J; Davidson RN
    Ann Trop Med Parasitol; 2006 Apr; 100(3):223-7. PubMed ID: 16630379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PKDL--A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India.
    Ganguly S; Saha P; Chatterjee M; Roy S; Ghosh TK; Guha SK; Kundu PK; Bera DK; Basu N; Maji AK
    PLoS Negl Trop Dis; 2015; 9(10):e0004138. PubMed ID: 26485704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistent dermal lesions in a patient with previous history of visceral leishmaniasis.
    Jaiteh MB; İnkaya AÇ; Üner A; Elçin G; Ergüven S; Kurtulan O; Harxhi A; Akova M
    Parasitol Int; 2021 Feb; 80():102197. PubMed ID: 32920054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
    Guffanti M; Gaiera G; Bossolasco S; Ceserani N; Ratti D; Cinque P; Salmaso F; Gianotti N; Lazzarin A
    Am J Trop Med Hyg; 2008 Nov; 79(5):715-8. PubMed ID: 18981510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amphotericin B Deoxycholate Treatment of Post-Kala-Azar Dermal Leishmaniasis in India.
    Sundar S; Chakravarty J; Singh J; Verma D; Agrawal N; Dinkar A
    Am J Trop Med Hyg; 2024 Jul; 111(1):59-63. PubMed ID: 38834057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-kala-azar dermal leishmaniasis and leprosy: case report and literature review.
    Trindade MA; Silva LL; Braz LM; Amato VS; Naafs B; Sotto MN
    BMC Infect Dis; 2015 Nov; 15():543. PubMed ID: 26592919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: a preliminary report.
    Ramesh V; Avishek K; Sharma V; Salotra P
    Acta Derm Venereol; 2014 Mar; 94(2):242-3. PubMed ID: 23995012
    [No Abstract]   [Full Text] [Related]  

  • 40. Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.
    Mondal D; Kumar A; Sharma A; Ahmed MM; Hasnain MG; Alim A; Huda MM; Rahman R; Alvar J; Ahmed BN; Haque R
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007653. PubMed ID: 31415565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.